ArticleNature cancer2023

Clonal origin of KMT2A wild-type lineage-switch leukemia following CAR-T cell and blinatumomab therapy.

Tim H H Coorens et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.